KDM3A and ovarian carcinoma: Since the demethylating activity and biological functions of KDM3A resides in the catalytic subunit, it can be a potential druggable target for small molecules that specifically target the rigid catalytic domain and thus can be exploited to device a novel therapy to target-resistant ovarian cancer.